History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C  by Bryan-Marrugo, O.L. et al.
Medicina Universitaria. 2015;17(68):165--174
www.elsevier.es/rmuanl
REVIEW ARTICLE
History  and  progress  of antiviral  drugs:  From  acyclovir
to direct-acting  antiviral  agents  (DAAs)  for Hepatitis  C
O.L. Bryan-Marrugoa, J. Ramos-Jiménezb, H. Barrera-Saldan˜aa, A. Rojas-Martíneza,
R.  Vidaltamayoc, A.M. Rivas-Estillaa,∗
a Department  of  Biochemistry  and  Molecular  Medicine,  School  of  Medicine,  ‘‘Dr.  José  Eleuterio  González’’,  University  Hospital,
Universidad Autónoma  de  Nuevo  León,  Monterrey,  N.L.,  Mexico
b Department  of  Internal  Medicine,  School  of  Medicine,  ‘‘Dr.  José  Eleuterio  González’’,  University  Hospital,  Universidad
Autónoma de  Nuevo  León,  Monterrey,  N.L.,  Mexico
c Universidad  de  Monterrey,  Monterrey,  N.L.,  Mexico
Received  17  December  2014;  accepted  12  May  2015
Available  online  3  July  2015
KEYWORDS
Hepatitis  C  virus;
Antiviral  drugs;
Direct-acting
antiviral  agents
(DAAs)
Abstract  The  development  of  antiviral  drugs  is  a  very  complex  process.  Currently,  around  50
drugs have  been  approved  for  human  use  against  viruses  such  as  HSV,  HIV-1,  the  cytomegalo
virus, the  inﬂuenza  virus,  HBV  and  HCV.  Advancements  in  this  area  have  been  achieved  through
efforts and  technical  breakthroughs  in  different  scientiﬁc  ﬁelds.  The  improvement  in  the  treat-
ment of  HCV  infection  is  a  good  example  of  what  is  needed  for  efﬁcient  antiviral  therapy.  A
thorough description  of  the  events  that  lead  to  the  development  of  speciﬁcally  targeted  antivi-
ral therapy  or  HCV  (STAT-C)  could  be  useful  to  further  improve  research  for  treating  many  other
viral diseases  in  the  future.  Similar  to  HIV-1  and  HBV  treatment,  combination  therapy  along  with
personalized  medicine  approaches  have  been  necessary  to  successfully  treat  HCV  patients.  This
review  is  focused  on  what  has  been  done  to  develop  a  successful  HCV  therapy  and  the  drawbacks
along the  way.
©  2014  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma  México  S.A.  This  is
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by-nc-nd/4.0/).Abbreviations: TFT, triﬂouro-thymidine; HCV, Hepatitis C virus; IFN, interferon; SVR, sustained virologic response; STAT-C, speciﬁcally
targeted antiviral therapy for Hepatitis C; DAAs, direct-acting antiviral a
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ntroduction
rom  1972  to  date,  more  than  50  new  viruses  have  been
dentiﬁed  as  etiologic  agents  of  human  disease.1 These  new
iral  diseases  have  required  more  sophisticated  therapeutic
gents,  but  the  development  process  of  these  strategies  to
his  point  has  been  slow  and  full  of  hurdles.
Antiviral  chemotherapy  has  advanced  at  snail-like  pace,
nlike  antibiotics,  which  in  30  years  achieved  an  advanced
herapeutic  stage.  34  years  elapsed  from  the  description  of
he  antibacterial  molecule  salvarsan,  ‘‘the  magic  bullet’’,
y  Ehlrich  in  1910,2 to  the  discovery  of  penicillin  by  Fleming
n  1929,3 to  Domagk’s  description  of  prontosil,  the  precursor
f  sulfonamides  in  19354 and  the  isolation  of  streptomycin,
hloramphenicol,  erythromycin  and  tetracycline  by  Waks-
an  in  1944.5 However,  it  took  almost  60  years  for  antiviral
evelopment  to  reach  its  current  status  of  effectiveness.
he  evolution  of  the  treatment  for  Hepatitis  C  is  a  good
xample  of  how  complex  antiviral  development  can  be  and
ow  a  combined  and  speciﬁc  targeted  antiviral  therapy  has
roved  to  be  the  best  approach  to  follow  for  viral  disease
reatment.
The  Hepatitis  C  virus  (HCV)  affects  over  170  million  indi-
iduals  worldwide,  80%  of  which  are  chronically  infected.6
his  is  four  times  the  number  of  people  infected  with  HIV
nd  about  half  the  number  of  persons  infected  with  the
epatitis  B  virus  (HBV). 7 HCV  is  caused  by  a  hepatotropic
irus,  which  belongs  to  the  Flaviviridae  family,  genus  Hep-
civirus.  HCV  was  discovered  in  1989  and  its  viral  genome  is  a
.6  kb-long  positive  single-stranded  RNA.  It  encodes  a  single
olyprotein  precursor  of  3010  amino  acids  and  has  an  inter-
al  ribosome  entry  site  at  the  5′ untranslated  region.  This
olyprotein  precursor  is  co-translationally  processed  by  cel-
ular  and  viral  proteases  into  three  structural  proteins  (core,
1  and  E2)  and  seven  non-structural  proteins  (p7,  NS2,  NS3,
S4A,  NS4B,  NS5A  and  NS5B).8 The  structural  proteins  asso-
iate  with  the  genomic  RNA  and  a  viral  particle  is  assembled
nside  a  lipidic  envelope.
Treatment  for  HCV  infection  has  come  a  long  way.
etween  2001  and  2011,  a  standard  of  care  (SOC)  for  chronic
CV  infection  was  established  worldwide.  It  consisted  of
 combination  of  pegylated  interferon  (PEG-IFN)  and  riba-
irin  (RBV).  Nowadays,  new  speciﬁc  antiviral  agents  have
een  approved.  In  May  2011,  boceprevir  and  telaprevir,  two
rst-generation  NS3/4A  protease  inhibitors,  were  autho-
ized  for  their  use  in  combination  with  PEG-IFN  and  RBV
or  a  24-to-48-week  course  of  treatment  in  HCV-genotype
 infections.  Two  years  later  (December  2013),  Simepre-
ir  (a  second-generation  NS3/4A  protease  inhibitor)  was
pproved  for  use  with  PEG-IFN  and  RBV  for  a  12-week
ourse  of  treatment  in  HCV-genotype  1,  while  sofosbu-
ir  (a  NS5B  nucleotide  polymerase  inhibitor)  was  approved
or  use  with  PEG-IFN  and/or  RBV  for  a  12/24-week  course
f  treatment  in  HCV-genotypes  1  to  4.  IFN-free  regimens
ave  been  shown  to  give  better  results,  because  sofos-
uvir,  combined  with  simeprevir  or  an  NS5A  replication
omplex  inhibitor  (ledipasvir  or  daclatasvir),  with  or  with-
ut  RBV  for  a  12-week  treatment  in  genotype  1,  resulted
n  a  sustained  virological  response  (SVR)  >90%.  In  addition,
BT-450/r  (ritonavir-boosted  NS3/4A  protease  inhibitor)-
ased  regimens,  in  combination  with  other  direct-acting
ntiviral  agent(s)  with  or  without  RBV  for  12  weeks  in
t
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enotype  1,  have  demonstrated  similar  results  regarding
VR.9
oadblocks for  antiviral drug development
s  we  see  in  the  text  above,  therapy  for  HCV  infection
emained  almost  the  same  from  2001  to  2011.  After  a  decade
f  poorly  effective  HCV  therapy,  the  development  of  speciﬁc
ompounds  against  this  virus  ramped  up  HCV  treatment  on
 pace  that  nearly  matched  antiretroviral  therapy  for  HIV.
‘Why  did  it  take  such  a  long  time?’’  is  an  important  question
hose  answer  could  help  on  the  approaches  towards  drug
evelopment  against  untreated  diseases.  The  ﬁrst  complica-
ion  when  studying  a  virus  is  the  limitations  regarding  in  vitro
ystems  and  animal  models  for  experimentation;  second,  is
he  low  rate  of  discovery  for  efﬁcient  candidate  molecules,
nd  third,  the  delicate  balance  between  efﬁcacy,  toxicity
nd  resistance  towards  the  selected  antiviral  drug.  Addi-
ional  economical  aspects  must  also  be  considered.  Here  we
ave  analysed  each  of  these  aspects  under  the  light  of  the
romises  and  pitfalls  related  to  Hepatitis  C  research  and
reatment.
CV study tools
iruses  are  intracellular  organisms  which  depend  on  cellular
achinery  for  replication.  Therefore,  a  huge  breakthrough
n  this  ﬁeld  was  achieved  by  Enders,  Robbins  and  Weller
n  1951,  when  they  developed  an  in  vitro  virus  propaga-
ion  system  in  cell  culture.10 Since  then,  many  in  vitro  and
n  vivo  systems  have  been  implemented  for  the  study  of
everal  viruses,  such  as  polio  and  HIV.  Cell  assays  systems
ere  recently  developed  for  HCV  infection  and  propaga-
ion.  In  the  early  beginnings  of  HCV  studies,  no  small  animal
odel  existed  to  study  HCV  infections,  and  Chimpanzees,
he  only  animals  capable  of  being  infected  with  HCV,  were
recluded  by  both  ethical  and  functional  difﬁculties.  The
n  vitro  development  for  HCV  research  began  with  the
ub-genomic  replicon  cell  culture  system  that  replicates
utonomously  in  the  human  hepatoma  cell  line  Huh-7  gener-
ted  by  Bartenschlager  et  al.,  in  2001.11,12 This  sub-genomic
eplicon  model  was  further  improved  by  the  identiﬁcation
nd  introduction  of  adaptive  mutations,  which  enhanced
irus  replication  capacity  and  lead  to  the  establishment  of
he  full-length  replicon  system  using  the  highly  permissive
ell  line  Huh-7.5.1  in  2003,  by  Blight  and  Bartenschlager
t  al.,  separately.13--15 These  developments  allowed  the
tudy  of  HCV  infection  mechanisms,  such  as  packaging,  bud-
ing  and  a  more  accurate  evaluation  of  potential  antiviral
olecules.  On  the  other  hand,  the  development  of  a  small
nimal  model  that  can  be  infected  with  HCV  became  a
eality  with  the  T-  and  B-cell  deﬁcient  mice  with  severe
ombined  immunodeﬁciency  (SCID),  grafted  with  human
epatocytes.  The  ﬁrst  HCV  infection  studies  in  this  model
ere  performed  by  Mercer  et  al.  in  2001.  In  recent  years
he  development  of  transgenic  mice  with  a  chimeric  mouse-
uman  liver  revolutionized  HCV  infection  research,  allowing
he  assessment  of  pathological  and  immunological  proﬁles
f  the  disease.16 Today,  scientists  rely  on  a  combination  of
ntiviral  activity  assessment  in  the  HCV  replicon  cell  culture
ystem,  cell-based  infection  systems,  and  pharmacokinetic
t
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proﬁling  in  animals  as  proxy  indicators  of  antiviral  drugs’
efﬁcacy,  before  attempting  clinical  trials.17
Screening process for antiviral drug discovery
Another  aspect  that  made  antiviral  drug  discovery  a  difﬁ-
cult  endeavor  was  the  lack  of  a  structured  and  systematic
method  for  antiviral  drug  development.  Three  decades  ago
most  of  the  ﬁrst  discoveries  of  antiviral  compounds  were
fortuitous,  since  molecules  originally  developed  for  other
purposes  were  selected  as  antiviral  candidates,  based  on
their  success  in  other  medical  disciplines.  These  meth-
ods  for  antiviral  discovery  were  empirical,  and  most  of
the  time,  the  biological  mechanism  behind  the  observed
antiviral  effect  remained  unclear.  For  instance,  the  use  of
thio-semicarbazones  against  the  vaccinia  virus,  described  in
1950  by  Hamre  et  al.,  and  used  later  as  an  antibacterial  drug
against  tuberculosis.18 In  1959,  the  5-iodo-2-deoxyuridine
(IDU),  which  was  originally  designed  for  cancer  treatment,
proved  to  exhibit  antiviral  activity  against  the  Herpes  Virus,
but  due  to  its  high  cytotoxicity,  its  use  was  limited  to  topical
application.  IDU  boosted  antiviral  development,  and  from
its  discovery  many  antiviral  molecules  were  proposed  for
the  treatment  of  various  viral  diseases.19 In  Fig.  1,  a  time
line  of  the  milestones  in  the  development  of  antiviral  agents
shows  the  early  years  of  this  discipline  and  how  it  evolved  to
become  a  structured  and  methodic  science.20 At  the  time  of
IDU  discovery,  only  a  handful  of  viruses  were  known  to  cause
diseases  in  humans.  The  ﬁrst  antiviral  drugs  were  directed
to  treat  herpes,  polio,  smallpox  and  inﬂuenza,  as  they  were
the  most  relevant  viral  diseases  of  that  time.  Some  of  them
t
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Figure  1  Evolution  of  antiviral  drug  discovery.  From  the  beginnin
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hat  we  can  mention  are  the  following:  triﬂouro-thymidine
TFT),  a  nucleoside  analogue  used  to  treat  herpes;  ade-
ine  arabinoside  (Ara-A)  a  nucleoside  analogue  against  the
erpes  simplex  virus21; 2-(-hydroxybenzyl)  benzimidazole
or  the  treatment  of  poliomyelitis;  Marboran  for  the  treat-
ent  of  smallpox  and  amantadine  and  rimantadine  to  treat
nﬂuenza,  which  were  identiﬁed  by  traditional  biological
creening  assays  in  the  early  1960s  and  was  shown  to
e  inhibitory  for  inﬂuenza  A  viruses  in  cell  culture  and
nimal  models.  In  the  last  two  decades,  medicinal  chem-
stry  has  developed  into  a  recognized  discipline,  in  which
 lead  compound  was  usually  identiﬁed  by  screening  a
arge  collection  of  molecules.  This  method  was  improved
ith  the  introduction  of  combinatorial  chemistry  and  high-
hroughput  screening.22 Today,  more  structured  rationales
re  implemented  when  looking  for  new  antiviral  drugs;  sim-
le  screening,  blind  screening  and  programmed  screening
ave  become  more  sophisticated,  as  the  tools  to  ana-
yze  structure,  protein  interaction  and  viral  behavior  have
volved.  For  HCV  therapy  development,  many  attempts  to
reat  the  infection  were  implemented,  with  rather  poor
esults.23 Due  to  the  lack  of  a  serological  test,  systematic
reatment  protocols  could  not  be  performed,  and  so  several
‘informal’’  studies  were  reported,  evaluating  many  kinds  of
olecules.  But  it  was  not  until  1986  that  Hoofnagle  reported
he  beneﬁcial  effect  of  Interferon  Alpha  in  a  pilot  study  to
reat  Non-A/Non-B  hepatitis.24 This  report  primed  a  boom  in
CV  therapeutics  and  many  randomized  controlled  clinical
rials  were  performed  to  improve  HCV  treatment.  In  1990
ibavirin  was  ﬁrst  proposed  to  treat  HCV  infection  and  the
rst  clinical  trial  for  the  assessment  of  its  efﬁcacy  began
n  1991.25,26 After  the  efﬁcacy  of  the  combined  antiviral
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Figure  2  HCV  Potential  targets  for  antiviral  chemotherapy.  Many  targets  for  antiviral  action  can  be  found  along  HCV’s  life  cycle.
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aherapy  of  Pegylated  Interferon- (PEG-IFN-)  and  ribavirin
gainst  HCV  infection  was  proven,  it  became  the  standard  of
are  (SOC)  for  this  disease,  and  despite  its  shortcomings  (50%
esponse  rate  and  50%  relapse  rate  on  patients  infected  with
enotype  1b,  and  unwanted  side  effects),  it  remained  as
uch  for  more  than  15  years.27,28 During  this  time,  using  blind
creening  approaches,  some  molecules  were  found  to  reduce
CV-RNA  levels  in  vitro, but  none  of  them  were  signiﬁcant
nough  to  be  implemented  clinically.  It  was  not  until  May,
011  that  the  improved  understanding  of  the  HCV  life  cycle
ed  to  the  discovery,  assessment  and  FDA  approval  of  the  HCV
rotease  inhibitors  Telaprevir  and  Boceprevir,  that  effec-
ively  reduce  viral  load  on  chronic  HCV  infected  patients,
n  treatment  of  naïve  patients  and  in  prior  relapsers  and
on-responders. 29,30 Telaprevir  and  boceprevir  were  the  ﬁrst
irect-acting  antiviral  agents  (DAAs)  that  selectively  target
CV.  However,  new  DDAs  have  been  recently  added  to  this
ist:  simeprevir  (protease  inhibitor),  sofosbuvir  (NS5b  poly-
erase  inhibitor),  daclatasvir  (NS5A  protein  inhibitor),  and
aldaprevir  (second-wave  NS3/4A  protease  inhibitor),  all  of
hem  showing  very  promising  results  and  some  have  even
een  proposed  as  the  treatment  backbone  for  Interferon-
ree  HCV  therapies.31,32 With  these  selective  HCV  protease
nhibitors,  the  establishment  of  STAT-C  therapy  became
 reality.  Today,  several  DAAs  (including  HCV  protease
nhibitors,  polymerase  inhibitors,  and  NS5A  inhibitors)  are  in
arious  stages  of  clinical  development.  Current  research  is
ttempting  to  improve  the  pharmacokinetics  and  tolerabil-
ty  of  these  agents,  deﬁne  the  best  regimens,  and  determine
reatment  strategies  that  produce  the  best  outcomes.  Some
f  these  DAAs  will  reach  the  market  simultaneously,  and
esources  will  be  needed  to  guide  the  use  of  these  drugs.  It
s  also  worth  mentioning  that  different  lines  of  research  are
urrently  evaluating  other  ways  to  improve  HCV  chemother-
py.  For  example,  taribavirin,  a  prodrug  for  the  long-known
ucleoside  analogue  ribavirin,  is  at  3rd  phase  clinical  tri-
ls  and  has  shown  promising  results.33 This  new  antiviral
ould  further  boost  HCV  therapy  in  the  coming  years.
f
i
O
eig.  2  shows  the  major  HCV  potential  targets  for  antiviral
hemotherapy.
fﬁcacy and toxicity on the development of an
fﬁcient antiviral drug
ince  the  discovery  of  IDU  50  years  ago,  only  a  few  molecules
ave  proven  to  be  effective  and  safe  when  used  for  selec-
ive  antiviral  therapy.  A  huge  breakthrough  that  came
rom  the  better  understanding  of  virus-host  interaction  was
he  inception  of  9-(2-hydroxyethoxymethyl)  guanine  (Acy-
lovir).  It  was  the  ﬁrst  highly  selective  antiviral  drug,  being  a
ubstrate  for  the  Herpes  Simplex  Virus-encoded  thymidine-
inase.  It  displayed  a  direct  inhibitory  effect  against  viral
eplication  and  practically  no  adverse  effects  on  the  host.
he  achievement  of  selective  viral  toxicity  by  Acyclovir  and
ther  similar  molecules  were  thought  of  as  the  beginning
f  a new  therapeutic  age  for  a  well-established,  effective
nd  safe  antiviral  therapy.  Acyclovir  is  a pro-drug,  which
eans  it  has  to  be  further  metabolized  in  vivo  before  enter-
ng  the  infected  cell  wherein  further  metabolism  may  or
ay  not  be  required  to  yield  the  active  inhibitor.  The  key
o  Acyclovir’s  speciﬁcity  is  the  selective  phosphorylation
f  the  acyclic  guanosine  nucleoside  by  the  Herpes  virus-
ncoded  pyrimidine  deoxynucleoside  kinase,  which  means
t  would  only  be  active  on  Herpes-infected  cells.34 After
cyclovir’s  discovery  and  study,  several  nucleoside  analog
ro-drugs  have  been  developed,  all  of  them  with  relatively
igh  speciﬁcity  (Table  1  shows  a  list  of  the  most  important
ntiviral  drugs,  including  their  mode  of  action).  Sadly,  new
hallenges  arose  for  antiviral  treatment.  Several  resistant
utants  have  been  identiﬁed,  making  it  more  difﬁcult  to
chieve  a complete  viral  eradication  and  therefore  demands
or  a  successful  antiviral  therapy  became  more  complex,
nvolving  many  aspects  that  were  previously  not  considered.
ne  undeniable  fact  is  that  most  of  our  current  knowl-
dge  on  viral  and  antiviral  science  comes  from  the  study  of
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Table  1  Major  antiviral  compounds  developed  and  approved  for  use  in  humans.
Name  Class  Target  virus  Year  of  discovery
-Thiosemicarbazone IMINE  DERIVATIVE BROAD  SPECTRUM  1949
INTERFERON  CYTOKINE  (Immunomodulator)  BROAD  SPECTRUM  1954,  1957
IDU NA  HERPES  SIMPLEX  1959
HYDROXYBENZYL-BENZIMIDAZOLE  UD  BROAD  SPECTRUM  1961
MARBORAN UD  DNA  VIRUSES  1963
TFT NA  HERPES  SIMPLEX  1964
AMANTADINE,  RIMANTADINE  UD  INFLUENZA  1964
ARA-A NA  HERPES  SIMPLEX  1964
ACICLOVIR NA  HERPES  1971
RIBAVIRIN NA  BROAD  SPECTRUM 1972
DHPA-dihydroxypropyladenine NA  BROAD  SPECTRUM 1978
Phosphonoformicacid  (FOSCARNET)  PA  HERPES,  CYTOMEGALOVRUS  1979
BVDU (Brivudin)  NA  HERPES  1979
GANCICLOVIR  NA  HERPES,  CYTOMEGALOVRUS  1982
AZIDOTHIMIDINE  (AZT,  zidovudine)  NARTI  HIV  1985
DDC (HIVID,  Zalcitabine)  NARTI  HIV  1986
DDL (VIDEX,  didanosine)  NARTI  HIV  1987
D4T (SERIT,  Stavudine)  NARTI  HIV  1987
CIDOFOVIR NA  CMV  1988
FAMCICLOVIR  NA  HERPES  SIMPLEX  1989
HEPT/TIBO  NNRTI  HIV  1990
NEVIRAPINE  (Viramune)  NNRTI  HIV  1990
3TC (Epivir,  Lamivudine)  NARTI  HIV  1991
SAQUINAVIR  PI  HIV  1991
DOCONASOL  FI  HERPES,  SINCYTIAL  VIRUS  1991
ZANAMIVIR (RELENZA)  NI  INFLUENZA  1993
DELAVIRDINE  (RECRIPTOR)  NNRTI  HIV  1993
INDINAVIR (CRIXIVAN)  PI  HIV  1994
TENOFOVIR  NA  HIV  1995
EFIVARENZ NNRTI  HIV  1995
AMPRENAVIR  (AGENERASE) PI  HIV  1995
RITONAVIR (NORVIR) PI  HIV  1995
ENFUVIRTIDE FI  HIV  1996
OSELTAMIVIR  (TAMIFLU) NI  INFLUENZA  1997
LOPINAVIR PI  HIV  1998
ENTECAVIR NA  HEPATITIS  B 2000
PERAMIVIR NI  INFLUENZA  2000
ADEFOVIR NARTI  HBV  2000
ATAZANAVIR  PI  HIV  2000
DARUNAVIR  PI  HIV  2003
TARIBAVIRIN  NA  BROAD  SPECTRUM  2003
TELAPREVIR  PI  HCV  2004
MARAVIROC  RA  HIV  2005
RALTEGRAVIR  II  HIV  2005
BOCEPREVIR  PI  HCV  2006
ELVITEGRAVIR  II  HIV  2006
NA: nucleoside analogue; NARTI: nucleoside analogue-reverse trancriptase inhibitor; UD: undetermined; PA: pyrophosphate analogue;
NNRTI: non-nucleoside analogue-reverse trancriptase inhibitor; NARTI: nucleoside analogue-reverse trancriptase inhibitor; PI: protease
epto
H
cinhibitor; FI: fusion inhibitor; NI: neuraminidase inhibitor; RA: rec
HIV.  The  science  of  antiviral  research  was  well  established
when  HIV/AIDS  appeared  as  a  major  viral  disease  in  early
1980s.  An  increase  of  antiviral  therapy  studies  with  no  equal
took  place  when  the  ﬁrst  cases  of  HIV  were  reported.  Azi-
dothymidine  (AZT),  among  other  antiviral  molecules  already
in  existence,  proved  to  have  selective  toxicity  against  HIV.
w
y
l
vr antagonist; II: integrase inhibitor.
owever,  it  was  during  the  treatment  of  HIV  that  medicine
onfronted  new  obstacles.  The  concept  of  resistant  strains
as  long  known  in  the  microbiological  world,  but  for  the
oung  and  developing  antiviral  terrene,  it  was  an  issue  of
ittle  importance  until  then.  HIV  was  one  of  the  ﬁrst  chronic
iral  diseases  discovered  to  have  a  considerable  impact
170
 
O
.L.
 Bryan-M
arrugo
 et
 al.
Table  2  Summary  of  the  recent  treatment  guidelines  for  HCV  infection  therapy  [described  by  the  American  Association  for  the  Study  of  Liver  Diseases  (AASLD),  Infectious
Disease Society  of  America  (IDSA)  and  the  International  Antiviral  Society  (IASUSA)].
HCV  genotype  Naïve  patientsb Non-responders  to  traditional  IFN-RBV
therapy
Resistant  to
Sofosbuvir
Resistant  to
traditional
therapy  and  1st
generation
protease
inhibitors
Patients  with
Cirrhosisb
1a Combination  of  Ledispavir  90  mg/sofosbuvir
400 mg  for  12  wks
Combination  of  Ledispavir  90  mg/sofosbuvir
400 mg  for  12  wks
Combination  of
Ledispavir
90  mg/sofosbuvir
400  mg  for  12
wks
Extend
treatment  for
24  wks
Paritaprevir 150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  and  RBVa for  12  wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  and  RBVa for  12  wks
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa for  12
wks.
Extend
treatment  for
24  wks
Sofosbuvir 400  mg/Simeprevir  150  mg/RBVa
for  12  wks
Sofosbuvir  400  mg/Simeprevir  150  mg/RBVa
for  12  wks
Extend
treatment  for
24  wks
1b Ledipasvir 90  mg/sofosbuvir  400  mg  for  12
wks
Ledipasvir  90  mg/sofosbuvir  400  mg  for  12
wks
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  for  12
wks
Extend
treatment  to
24  wks
Paritaprevir 150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  for  12  wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  for  12  wks
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa for  12
wks.
Plus  RBV
Sofosbuvir 400  mg/Simeprevir  150  mg  for  12
wks
Sofosbuvir  400  mg/Simeprevir  150  mg  plus
RBVa for  12  wks
Extend
treatment  for
24  wks
2 Sofosbuvir 400  mg  and  RBVa for  12  wks  Sofosbuvir  400  mg  and  RBVa for  12  wks  Extend
treatment  for
16  wks
Sofosbuvir 400  mg  and  RBVa plus  weekly
PEG-IFN  for  12  wks
3 Sofosbuvir  400  mg/RBVa Sofosbuvir  400  mg  and  RBVa for  12  wks
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Table  2  (Continued)
HCV  genotype Naïve  patientsb Non-responders  to  traditional  IFN-RBV
therapy
Resistant  to
Sofosbuvir
Resistant  to
traditional
therapy  and  1st
generation
protease
inhibitors
Patients  with
Cirrhosisb
Sofosbuvir  400  mg/RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  and  RBVa plus  weekly
PEG-IFN  for  12  wks
4 Ledipasvir  90  mg/Sofosbuvir  400  mg  for  12
wks
Ledipasvir  90  mg/Sofosbuvir  400  mg  for  12
wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/and  RBVa for  12
wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/and  RBVa for  12
wks
Sofosbuvir  400  mg/RBVa for  24  wks Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa for  24  wks
5 Sofosbuvir 400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Weekly  PEG-IFN  plus  RBVa for  48  wks  Weekly  PEG-IFN  plus  RBVa for  48  wks
6 Ledispavir  90  mg/Sofosbuvir  400  mg  for  12
wks
Ledispavir  90  mg/Sofosbuvir  400  mg  for  12
wks
Sofosbuvir  400  mg  plus  RBVa plus  weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  weekly
PEG-IFN  for  12  wks
a RBV (Ribavirin) dosage is weight based (1000 mg [<75 kg] and 1200 mg [>75 kg]).
All indications refer to daily doses unless is otherwise clariﬁed in the text.
b Deﬁnitions for treatment criteria.42,43
(Treatment) Naïve patient: A person who has never undergone any HCV therapy.
-- Rapid Virologic Response (RVR): It is deﬁned as an undetectable HCV RNA at week 4 of treatment.
-- Sustained Virological Response (SVR): It is deﬁned as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion.
-- Non-response: Refers to a patient who do not achieve undetectable HCV RNA during the ﬁrst 24 weeks of treatment. There are two forms of non-responders: Partial responders and
null responders.
-- Partial response: It is a sub-category of non-response and describes a decrease in HCV RNA levels by at least 2 Log10 at week 12 of treatment but detectable levels at week 24.
-- Null response: Is a sub-category of non-response and refers to the situation when a patient does not suppress their HCV RNA levels by at least 2 Log10 by week 12 of treatment.
-- Drug resistant: A patient who is Partial or Null responder to a speciﬁc treatment for which a HCV ‘‘resistant’’ mutant remains immune making necessary to change the therapeutical
approach.
-- Liver Cirrhosis: Liver disease severity should be assessed prior to therapy. Identifying patients with cirrhosis is of particular importance as their prognosis is altered and their treatment
regimen may be adapted. Liver biopsy remains the reference method for grading the activity and histological progression (staging) of the disease (ﬁbrosis and cirrhosis). Some non-invasive
methods can also be used: Assessment for Liver stiffness, muscle atrophy, patient skin, sclera and mucous; skin turgor, jaundice, spider angiomas and palmar erythema along with elevation
of liver enzymes (AST, ALT and LDH). Patients with liver cirrhosis must also be assessed for Hepatocellular Carcinoma.
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n  public  health.  Although  antiviral  research  and  develop-
ent  were  ignited  by  the  HIV  threat,  many  HIV  patients
ere  not  responsive  to  the  treatment.  The  discovery  of  AZT
as  followed  by  several  other  dideoxynucleoside  (ddN)  ana-
ogues  (ddI,  ddC,  d4T,  3TC,  ABC,  FTC)  (Fig.  2).  All  these
RTIs  act  in  a  similar  fashion;  after  their  phosphorylation
o  triphosphates,  they  interact  as  ‘chain  terminators’  of
he  HIV-reverse  transcriptase,  thus  preventing  the  formation
f  the  proviral  DNA.  Even  though  they  had  great  success,
rug  resistance  forced  HIV  treatment  to  evolve.  Today,  it
s  known  that  two  inevitable  and  important  consequences
f  antiviral  therapy  have  to  be  taken  into  account  when
lanning  a  treatment  strategy  for  viral  chronic  diseases.
he  ﬁrst  is  that,  given  its  nature,  long-term  antiviral  ther-
py  automatically  selects  resistant  mutants  that  will  survive
nd  become  dominant  strains.  Resistant  mutants  are  even
ore  frequent  in  viral  than  in  bacterial  infection,  and  this
ecomes  more  evident  when  treating  chronic  viral  infections
uch  as  HIV  and  HCV.35--37 For  viral  infections,  any  attempt
o  attack  the  virus’  metabolism  could  have  an  effect  on  host
ells.  It  is  evident  then,  that  modiﬁcations  of  these  two
spects  of  antiviral  therapy,  could  improve  the  results  of
reatment  for  chronic  patients.  This  barrier  was  overcome
n  part  through  the  use  of  combinatorial  therapy.  In  addi-
ion  to  that,  the  concept  of  a  broad  spectrum  or  at  least  a
‘pangenotypic’’  antiviral  molecule  that  could  be  effective
n  a  wide  range  of  viral  pathogens  is  paradoxically  self-
efeating  if  we  think  that  speciﬁcity  is  required  to  avoid  cell
oxicity  and  the  opposite  is  needed  to  broaden  the  spectrum
f  a  given  antiviral  molecule.  With  our  current  knowledge
n  viral  metabolism  and  host  interaction,  three  aspects  of
iral  infection  can  be  targeted  for  antiviral  treatment:  inhi-
ition  of  viral  genes  and  proteins,  blocking  of  host  genes  and
nzymes  that  interact  with  viral  counterparts,  and  modula-
ion  of  host  metabolic  pathways  involved  in  the  virus  life
ycle.
he challenges of ﬁghting Hepatitis C
s  we  mentioned  before,  a  new  era  of  therapeutics  is
urrently  emerging  for  Hepatitis  C  treatment,  since  sev-
ral  other  direct-acting  HCV  antiviral  drugs  are  being
eveloped  (Protease  inhibitors:  faldaprevir,  asunaprevir,
anoprevir,  vaniprevir,  ABT-450-ritonavir,  MK5172,  GS-9451;
S5A  inhibitors:  ledipasvir,  ombitasvir,  GS-5816,  PPI-668,
K-8742  and  daclatasvir;  NS5b  inhibitors:  mericitabine,
X-135,  dasabuvir,  BMS-791325,  GS-9669),  which  have  been
hown  to  reduce  viral  RNA  levels,  reaching  SVR  in  up  to
5%  of  the  treated  patients.38,39 However,  there  are  several
hallenges  to  be  addressed  to  combat  HCV  using  new  drugs.
AA’s  directly  attack  the  Hepatitis  C  virus  and,  similar  to
ome  of  the  drugs  used  to  treat  HIV,  these  new  molecules
arget  the  enzymes  needed  for  viral  protein  processing;  the
irus  should  counterpart  this  effect  (Fig.  2).  Based  on  that,
CV  genetic  variability  and  drug  resistance  are  the  bigger
bstacles  that  DAAs  must  overcome.  HCV  has  a  high  rate
f  replication,  with  1012 virions  produced  daily,  along  with
n  equally  high  mutation  rate,  meaning  that,  for  any  given
rug,  there  are  already  resistant  mutants  present  on  the
nfected  subject  that  would  ultimately  render  single  drugs
seless.  However,  Hepatitis  C  resistance  may  be  delayed  or
n
i
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revented  by  using  combinations  of  potent  antiviral  drugs
ithout  cross-resistance  proﬁles  and  optimizing  patient
dherence  to  therapy.38 On  the  other  hand,  accessibility
o  the  new  and  approved  HCV  therapies  is  a  challenge  in
ombating  the  Hepatitis  C,  mainly  because  of  the  high
ost  of  the  combined  treatments  (between  100,000  and
50,000  USD).  Availability  and  accessibility  of  new  protease
nhibitors  (PI),  telaprevir,  boceprevir,  simeprevir,  and  the
ecently  approved  RNA  polymerase  inhibitor  (RPI)  sofosbuvir
epends  on  the  region  where  patients  are  located  and  their
ccess  to  governmental  health  programs.  In  most  countries,
ccessibility  to  these  drugs  is  possible  only  for  those  patients
ho  can  afford  treatment  for  themselves,  as  public  health
ystems  do  not  yet  have  policies  for  application  of  the  new
CV  therapy  to  the  general  population  through  insurance
ystems.40 This  will  likely  require  concerted  public  and
olitical  mobilization  to  pressure  originator  companies  to
educe  prices  and  stimulate  generic  competition.  In  addi-
ion,  lower  prices  could  make  widespread  access  to  HCV
reatment  possible  in  low  and  middle  income  countries.
here we stand today
fter  almost  20  years  since  HCV’s  discovery,  today  we
ccount  for  a  solid-yet-not-completely  effective  treat-
ent  landscape  to  ﬁght  hepatitis  infection.  First,  modern
iomolecular  diagnostic  tools  are  used  to  determine  geno-
ype  and  viral  load  as  a base  to  design  an  accurate
herapeutic  regimen;  second,  viral  load  dynamics  is  moni-
ored  in  order  to  determine  drug  resistance,  and  third  the
iver’s  state  and  the  presence  of  infection  are  assessed  in
atients  who  have  completed  the  therapy.  In  an  effort  to
rovide  a  condensed  set  of  treatment  guidelines,  the  Amer-
can  Association  of  Liver  Disease  (AASL),  Infectious  Disease
ociety  (IDSA)  and  the  International  Antiviral  Society  (IAS-
SA)  generated  the  Guidelines  for  HCV  infection  treatment
hich  are  based  on  patient’s  previous  exposure  to  treat-
ent,  HCV  genotype,  relapsing  proﬁle  and  hepatic  status.41
n  Table  2  we  show  a  compendium  of  the  recent  treatment
uidelines  for  HCV  infection  therapy.  It  is  important  for
hysicians  to  evaluate  patient  clinical  history  (naïve  or  not),
CV  genotype,  treatment  effectiveness  and  HIV  co-infection
n  order  to  avoid  unwanted  drug  interactions.
onclusions and perspectives
ntiviral  therapy  is  a  well-established  discipline  with
 promising  future.  Based  on  economic,  scientiﬁc  and
edical  interest,  and  a  continuous  need  for  new  drugs  to
void  resistance,  it  is  most  likely  that  the  development
f  antiviral  drugs  over  the  next  20  years  will  be  focused
n  HIV  and  HCV.  Today,  well-established  diagnostic  and
tudy  systems  are  available  for  HCV  and  other  viruses.  New
argets  against  HCV,  such  as  inhibitors  for  the  scavenger
eceptor  type  B1  (SR-B1)  and  CD81,  neutralizing  antibodies
gainst  the  viral  glycoproteins  and  the  NS5B  polymerase,
s  well  as  the  NS2/3  auto-protease,  the  NS3  helicase,  and
on-enzymatic  targets  such  as  NS4B  and  NS5A  proteins  are
n  development  (Fig.  1).  Other  potential  drugs  targeting
CV  replication  include  compounds  active  against  the  IRES
lement  and  antisense  inhibition.  As  mentioned  before,
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virus  factors  are  not  the  only  potential  targets  for  inhibition,
but  host  targets  are  as  well,  including  microRNAs,  cellular
receptors,  adhesion  molecules  and  cyclophilins.  For  the
near  future,  a  combination  of  host  and  viral  inhibitors  will
provide  a  variety  of  drug  regimes  appropriate  for  different
patients  that  could  lead  to  interferon-free  therapies  that
can  consistently  clear  the  infection.
A  new  era  of  HCV  treatment  and  the  increasing  knowl-
edge  about  viruses  and  their  mechanisms  of  infection,
combined  with  the  rapid  discovery  of  novel  antiviral  strate-
gies  and  techniques,  will  speed  up  the  development  of  novel
antiviral  drugs.
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